Biotech investing saw growth in 2024, with RA Capital leading VCs. FDA cancels flu vaccine meeting, Pfizer hires ex-FDA ...

Industry groups are looking to push government drug price negotiation and PBM reforms into a massive Republican domestic ...

CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...

Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price down ...

BridgeBio Oncology Therapeutics to go public via merger with Helix Acquisition Corp. II SPAC, led by Bihua Chen's Cormorant, ...

William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...

More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal ...

CDC investigating 5 hospitalizations in people 65+ for cardiac/neurologic events after receiving Valneva's Ixchiq chikungunya ...

John Coster, CMS' senior technical advisor for the Medicare drug rebate and negotiation group, told Endpoints News that he's ...

Color Health and OpenAI partnered with UCSF to develop an AI copilot for cancer screenings, publishing architecture details ...

Teladoc reports $1B net loss in 2024, including $790M impairment charge for BetterHelp. Revenue down 1% to $2.7B, shares fall ...

Hansoh exits siRNA deal with Silence Therapeutics, Vir seeks partner for hep B combo, Alopexx plans IPO, Medigene-EpimAb partner on T cell engagers, Belite Bio trial cleared ...